187 related articles for article (PubMed ID: 27419107)
1. Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy.
Kim SJ; Kim JH; Chang HK; Kim KH
J Exerc Rehabil; 2016 Jun; 12(3):143-7. PubMed ID: 27419107
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence.
Jo JK; Kim K; Lee SE; Lee JK; Byun SS; Hong SK
Ann Surg Oncol; 2016 May; 23(5):1760-7. PubMed ID: 26717939
[TBL] [Abstract][Full Text] [Related]
3. Sexual Rehabilitation After Nerve-Sparing Radical Prostatectomy: Free-of-Charge Phosphodiesterase Type 5 Inhibitor Administration Improves Compliance to Treatment.
Siena G; Mari A; Canale A; Mondaini N; Chindemi A; Greco I; Saleh O; Serni S; Nicita G; Minervini A; Carini M
J Sex Med; 2018 Feb; 15(2):120-123. PubMed ID: 29425663
[TBL] [Abstract][Full Text] [Related]
4. The "Kiel Concept" of Long-Term Administration of Daily Low-Dose Sildenafil Initiated in the Immediate Post-Prostatectomy Period: Evaluation and Comparison With the International Literature on Penile Rehabilitation.
Osmonov DK; Jünemann KP; Bannowsky A
Sex Med Rev; 2017 Jul; 5(3):387-392. PubMed ID: 28372960
[TBL] [Abstract][Full Text] [Related]
5. Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
Flores JM; Vertosick E; Jenkins LC; Cooper J; Benfante N; Sjoberg D; Vickers AJ; Eastham JA; Laudone VP; Scardino PT; Nelson CJ; Mulhall JP
J Urol; 2024 Mar; 211(3):400-406. PubMed ID: 38194487
[TBL] [Abstract][Full Text] [Related]
6. Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis.
He Q; Liao BH; Xiao KW; Zhou L; Feng SJ; Li H; Wang KJ
Int Urol Nephrol; 2018 Dec; 50(12):2113-2121. PubMed ID: 30232722
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
[TBL] [Abstract][Full Text] [Related]
8. The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer.
Peak TC; Richman A; Gur S; Yafi FA; Hellstrom WJ
Sex Med Rev; 2016 Jan; 4(1):74-84. PubMed ID: 27872007
[TBL] [Abstract][Full Text] [Related]
9. Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.
Kimura M; Caso JR; Bañez LL; Koontz BF; Gerber L; Senocak C; Donatucci CF; Vujaskovic Z; Moul JW; Polascik TJ
BJU Int; 2012 Dec; 110(11 Pt C):E931-8. PubMed ID: 22520165
[TBL] [Abstract][Full Text] [Related]
10. Persistent erectile dysfunction following radical prostatectomy: the association between nerve-sparing status and the prevalence and chronology of venous leak.
Tal R; Valenzuela R; Aviv N; Parker M; Waters WB; Flanigan RC; Mulhall JP
J Sex Med; 2009 Oct; 6(10):2813-9. PubMed ID: 19686421
[TBL] [Abstract][Full Text] [Related]
11. Prospective analysis of penile length changes after radical prostatectomy.
Berookhim BM; Nelson CJ; Kunzel B; Mulhall JP; Narus JB
BJU Int; 2014 May; 113(5b):E131-6. PubMed ID: 24053766
[TBL] [Abstract][Full Text] [Related]
12. Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
Aoun F; Slaoui A; Walid AHO; Albisinni S; Assenmacher G; de Plaen E; Azzo JM; Peltier A; Roumeguère T
Prog Urol; 2018 Oct; 28(12):560-566. PubMed ID: 30201551
[TBL] [Abstract][Full Text] [Related]
13. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
14. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.
Limoncin E; Gravina GL; Corona G; Maggi M; Ciocca G; Lenzi A; Jannini EA
Andrology; 2017 Sep; 5(5):863-872. PubMed ID: 28787547
[TBL] [Abstract][Full Text] [Related]
15. Utilization of pharmacotherapy for erectile dysfunction following treatment for prostate cancer.
Prasad MM; Prasad SM; Hevelone ND; Gu X; Weinberg AC; Lipsitz SR; Palapattu GS; Hu JC
J Sex Med; 2010 Mar; 7(3):1062-73. PubMed ID: 20059662
[TBL] [Abstract][Full Text] [Related]
16. Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo.
Pavlovich CP; Levinson AW; Su LM; Mettee LZ; Feng Z; Bivalacqua TJ; Trock BJ
BJU Int; 2013 Oct; 112(6):844-51. PubMed ID: 23937708
[TBL] [Abstract][Full Text] [Related]
17. Off-Target Effect of Sildenafil on Postsurgical Erectile Dysfunction: Alternate Pathways and Localized Delivery System.
Salmasi A; Lee GT; Patel N; Goyal R; Dinizo M; Kwon YS; Modi PK; Faiena I; Kim HJ; Lee N; Hannan JL; Kohn J; Kim IY
J Sex Med; 2016 Dec; 13(12):1834-1843. PubMed ID: 27843073
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Utility of Tacrolimus (FK506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy.
Mulhall JP; Klein EA; Slawin K; Henning AK; Scardino PT
J Sex Med; 2018 Sep; 15(9):1293-1299. PubMed ID: 30224019
[TBL] [Abstract][Full Text] [Related]
19. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME).
Shindel AW
J Sex Med; 2009 Jul; 6(7):1794-808; quiz 1793, 1809-10. PubMed ID: 19575771
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase-5 Inhibitor Use in Robot Assisted Radical Prostatectomy Patients Is Associated with Reduced Risk of Death: A Propensity Score Matched Analysis of 1,058 Patients.
Lee J; Kim HR; Heo JE; Jang WS; Lee KS; Kang SK; Han H; Choi YD
World J Mens Health; 2023 Oct; 41(4):892-899. PubMed ID: 36649919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
